 CAMBRIDGE, Mass., April 1, 2021 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the completion of enrollment for the first-line patient cohort in the DisTinGuish study, a clinical trial evaluating Leaps anti-Dickkopf-1 DKK1 antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd. 